Group 1 - The core viewpoint of the news is that the innovative insomnia drug Daridorexant (brand name: Kewico®) developed by the company in collaboration with Idorsia has been officially approved for marketing in China, enhancing patient access and supporting long-term use [1][2] - Daridorexant targets the orexin pathway in the hypothalamus, which is crucial for wakefulness, contrasting with traditional insomnia medications that act on GABA receptors to induce sedation [1] - The drug has shown significant clinical trial results, including reduced time to sleep onset and decreased wake time after sleep, with no serious adverse reactions reported during treatment [1] Group 2 - Daridorexant is the only DORA (Dual Orexin Receptor Antagonist) insomnia medication approved by the European Medicines Agency that improves daytime functioning, and it has been approved in 11 countries including the US, UK, and Japan [2] - The company entered into an exclusive licensing agreement with Idorsia for the development and commercialization of Daridorexant in the Greater China region, recognizing its market potential [2] - A supplementary agreement was reached between Idorsia and the company, involving a one-time cash payment of $50 million and adjustments to sales milestone payments and royalty rates, aimed at facilitating the commercialization of Daridorexant [2]
先声药业：与瑞士Idorsia公司合作的抗失眠创新药达利雷生在中国获批